Amplia Therapeutics Ltd
ASX:ATX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Amplia Therapeutics Ltd
Total Current Assets
Amplia Therapeutics Ltd
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Amplia Therapeutics Ltd
ASX:ATX
|
Total Current Assets
AU$36.1m
|
CAGR 3-Years
38%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Current Assets
$202.5m
|
CAGR 3-Years
37%
|
CAGR 5-Years
17%
|
CAGR 10-Years
4%
|
|
|
CSL Ltd
ASX:CSL
|
Total Current Assets
$11.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Total Current Assets
AU$21.2m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Current Assets
AU$330.3m
|
CAGR 3-Years
24%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Current Assets
AU$153.7m
|
CAGR 3-Years
81%
|
CAGR 5-Years
22%
|
CAGR 10-Years
32%
|
|
Amplia Therapeutics Ltd
Glance View
Amplia Therapeutics Ltd. is a medical biotechnology company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2013-12-23. The Company’s pipeline is developing two orally available small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its initial clinical development pipeline consists of AMP945 and AMP886 (FLT3/VEGFR3). The Company’s cancer program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its Fibrosis Program is the formation of excessive fibrous connective tissues that can result from chronic inflammation, chronic injury or disease. Its FAK inhibitors have been shown to block fibrosis in established animal models of both lung fibrosis and liver fibrosis (NASH).
See Also
What is Amplia Therapeutics Ltd's Total Current Assets?
Total Current Assets
36.1m
AUD
Based on the financial report for Sep 30, 2025, Amplia Therapeutics Ltd's Total Current Assets amounts to 36.1m AUD.
What is Amplia Therapeutics Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
50%
Over the last year, the Total Current Assets growth was 486%. The average annual Total Current Assets growth rates for Amplia Therapeutics Ltd have been 38% over the past three years , 50% over the past five years .
